Anjali Singh

Ceat to Apollo Tyres: Tyre makers find little grip on rising input costs

Ceat, JK Tyre, and Apollo Tyres signal further price hikes as surging rubber and crude-linked costs continue to squeeze margins

Aster DM Quality Care Q2 net profit more than doubles to ₹262 crore

The hospital chain reported revenue of ₹2,829 crore in Q2FY27, driven by higher patient volumes, improved occupancy, complex procedures and growth in medical value travel

M&M Q2 consolidated profit rises 25% to ₹4,588 cr on strong auto show

Auto business profit jumped 55 per cent as revenue grew 39 per cent, while the farm business saw lower sales and profitability amid a festive-season shift and margin pressure

Maharashtra's ₹8.6 trn litmus test: From investment promises to projects

Maharashtra secured investment commitments worth ₹8.57 trillion through 67 agreements in October, but land acquisition and power costs could slow their conversion into projects.

Glenmark Pharma Q2FY27 results: Net profit falls 57% to ₹264 crore

Consolidated revenue declined 29.8 per cent to ₹4,247 crore from ₹6,047 crore in Q2FY26

Biocon Q2 profit halves to ₹41 crore as delayed shipments weigh on margins

Biocon's Q2FY27 net profit fell 52 per cent to ₹41 crore as delayed shipments worth $20 million hit margins, while revenue rose 2 per cent to ₹4,389 crore.

HRV Pharma acquires German firm Phatebo, enters finished formulations biz

Hyderabad-based HRV Pharma acquires German clinical trial supplier Phatebo, which reported ₹350 crore revenue in 2025, marking its entry into Europe's finished formulations business

Emcure Pharma Q2FY27 net profit rises 34% to ₹325.5 crore, revenue up 24%

Emcure Pharmaceuticals reports 24.2 per cent revenue growth in Q2FY27, led by strong international sales, while domestic business expands 12 per cent and net profit rises 33.7 per cent

US FDA grants tentative nod to Dr Reddy's twice-yearly HIV prevention drug

The tentative approval for generic lenacapavir is expected to accelerate affordable access to the twice-yearly HIV prevention injection across 120 countries outside the US.

Syngene expects stronger H2 on order book, Zoetis supplies; retains outlook

Syngene International expects a stronger second half of FY27, driven by its order book and Zoetis supplies, while retaining guidance for a single-digit revenue decline.

Sun Pharma Q2 net profit falls 36% on one-time charges, revenue rises 12%

Exceptional charges of Rs 1,268.8 crore, including a US antitrust settlement and Organon acquisition costs, weighed on profit, while India formulation sales grew 17.3 per cent

BFSI Summit 2026: 'Digital access could widen MF investor base to 200 mn'

At the BFSI Insight Summit 2026, industry leaders said digital platforms, innovative SIP products, investor education and AI tools could help expand India's mutual fund base to 200 million.

Dr Reddy's net profit down 36% on lower Revlimid sales in North America

The company attributed the decline primarily to lower lenalidomide sales in North America. The base business, excluding lenalidomide in North America, continued to deliver double-digit growth

CDMO players bet on complex products such as biologics, peptides for growth

Next phase of growth hinges on biologics, peptides, and drug-device combinations, say industry executives

EV supply struggles to keep pace with surging demand during festive season

Electric vehicle sales rose 26% during Navratri as higher petrol prices boosted demand, but supply shortages, component constraints and rising bookings left dealers struggling to meet festive demand.

Dr Reddy's gets DCGI nod for cancer drug's second indication in India

The approval allows toripalimab with cisplatin and paclitaxel as first-line treatment for unresectable advanced, recurrent or metastatic ESCC in adults

Semaglutide mkt settles into steady growth six months after patent expiry

Generic brands now account for about 74% of monthly units as lower-priced products expand access, while doctors say the initial rush around the drug is cooling

Paras Health to use ₹375 cr from IPO to pare debt, plans 800-bed expansion

The ₹1,450-crore IPO comprises a ₹500-crore fresh issue and a ₹950-crore offer for sale, while the hospital chain plans to add 800 beds through projects in Gurugram and Ludhiana

Audi India bets on new models as it eyes double-digit growth next year

Luxury car market expected to grow 12%; festive quarter typically brings 20-25% rise in inquiries and conversions

Hyundai aims to regain No. 2 spot in India by 2028-29, says global CEO

Hyundai plans to regain its No. 2 position in India by 2028-29 through Pune plant expansion, 26 new models and investments in electric vehicles and greater localisation